seven children with central precocious puberty and either neurofibromatosis and/or optic gliomas were referred to the national institutes of health , bethesda , md , for evaluation and treatment with the long-acting luteinizing hormone releasing hormone analogue ( lhrha ) d-trp6-pro9-net-lhrh .
C0027831
neurofibromatosis
C0346326
optic gliomas